Emerging braf mutations in cancer progression and their possible effects on transcriptional networks

105Citations
Citations of this article
201Readers
Mendeley users who have this article in their library.

Abstract

Gene mutations can induce cellular alteration and malignant transformation. Development of many types of cancer is associated with mutations in the B-raf proto-oncogene (BRAF) gene. The encoded protein is a component of the mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK) signaling pathway, transmitting information from the outside to the cell nucleus. The main function of the MAPK/ERK pathway is to regulate cell growth, migration, and proliferation. The most common mutations in the BRAF gene encode the V600E mutant (class I), which causes continuous activation and signal transduction, regardless of external stimulus. Consequently, cell proliferation and invasion are enhanced in cancer patients with such mutations. The V600E mutation has been linked to melanoma, colorectal cancer, multiple myeloma, and other types of cancers. Importantly, emerging evidence has recently indicated that new types of mutations (classes II and III) also play a paramount role in the development of cancer. In this minireview, we discuss the influence of various BRAF mutations in cancer, including aberrant transcriptional gene regulation in the affected tissues.

References Powered by Scopus

Mutations of the BRAF gene in human cancer

9022Citations
N/AReaders
Get full text

New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer

2595Citations
N/AReaders
Get full text

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

2441Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients with BRAF <sup>V600</sup>-Mutant Metastatic Non-Small-Cell Lung Cancer

58Citations
N/AReaders
Get full text

The mechanism of activation of monomeric B-Raf V600E

51Citations
N/AReaders
Get full text

A recent update on small-molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry-based proteomic analysis

37Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020). Emerging braf mutations in cancer progression and their possible effects on transcriptional networks. Genes, 11(11), 1–14. https://doi.org/10.3390/genes11111342

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 34

77%

Researcher 8

18%

Professor / Associate Prof. 1

2%

Lecturer / Post doc 1

2%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 29

48%

Medicine and Dentistry 20

33%

Chemistry 6

10%

Agricultural and Biological Sciences 6

10%

Save time finding and organizing research with Mendeley

Sign up for free